Mounjaro Latest News: What Has Changed and What It Means for You

What did the Eli Lilly price change actually mean for people buying Mounjaro privately?

In August 2025, Eli Lilly announced a significant increase to Mounjaro's UK list price, taking effect from 1 September 2025. The list price of the highest-dose 15mg pen rose from roughly £122 to roughly £330, a change that fed through almost immediately into private prescription prices across the market. Before the increase, private monthly costs were often quoted in the low-to-mid hundreds; since then, reported private prices have ranged from around £149 to around £375 per month, varying by dose and provider.

It is worth understanding what that figure covers, or doesn't. Headline prices from some providers exclude the consultation fee, the prescription charge, and delivery costs. A lower list price from an unverified seller online is a different matter entirely: the MHRA has warned publicly about counterfeit weight-loss pens that have contained insulin rather than tirzepatide, with several hospitalisations reported. Any Mounjaro sourced through a seller that does not require a clinical assessment before supply is a serious safety concern, not a deal.

For a broader look at what drives private treatment costs and what a legitimate all-in price should include, our Mounjaro overview walks through the cost picture honestly. The short version: price is the wrong measure of value for a prescription medicine. Clinical oversight is the right one.

What did the NICE recommendation (TA1026) actually say, and who does it cover?

NICE published its appraisal of tirzepatide for weight management (TA1026) on 23 December 2024, with a further update in September 2025. The recommendation is specific: tirzepatide is recommended for NHS use in adults with a BMI of 35 or above who also have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI threshold is 2.5 kg/m² lower throughout.

NICE also sets a review point: if someone has not achieved at least 5% weight loss after six months at the highest tolerated dose, continuing treatment should be reconsidered. This is a clinical checkpoint built into the recommendation, not a hidden catch.

One thing TA1026 does not change is the private licensing threshold. Tirzepatide's UK licence covers adults with BMI ≥30, or ≥27 with at least one weight-related condition, broader than the NHS recommendation. That distinction matters for people considering the private route: more detail on tirzepatide's licensed eligibility criteria is available if you want to see exactly where you might stand before a consultation.

You can read NICE's recommendations chapter for TA1026 directly, it is plain enough to read without a medical background.

How is the NHS rollout actually progressing, and what does it mean if you're waiting?

The phased NHS rollout is real, but it is moving gradually. The first cohort (adults with BMI 40 or above plus four or more of the five qualifying conditions) became eligible from June 2025. Cohort 2, covering BMI 35–39.9 with four or more qualifying conditions, was activated on 23 June 2026. From around March 2027, the criteria are expected to widen to BMI ≥40 with three qualifying conditions.

From 1 April 2026, GP practices in England can prescribe tirzepatide under the new GP contract, but participation is optional, so what your practice offers depends on where you live. Every NHS patient must also take part in structured diet and activity support as part of their treatment. Meeting the criteria does not guarantee immediate access; waiting lists exist, and availability varies considerably by area.

If you do not meet the current NHS thresholds, or you would rather not wait, private prescription through a GPhC-registered pharmacy is the legal alternative, subject to clinical assessment. If you are curious about how the NHS and private routes compare in practice, this page on getting Mounjaro in the UK sets out both options without pushing you either way. For updates as the rollout phases change, you can find the latest tirzepatide news worth bookmarking, and our latest on Mounjaro is kept up to date as each new phase is confirmed.

What did SURMOUNT-5 actually find, and why does it matter now?

SURMOUNT-5 was a head-to-head trial comparing tirzepatide and semaglutide 2.4mg directly, something the earlier SURMOUNT-1 and STEP 1 trials could not do, since they each compared against placebo separately. Published in the New England Journal of Medicine in 2025, the trial ran for 72 weeks across 751 adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction than semaglutide over that period.

This is clinically meaningful because indirect comparisons between the two medicines had previously suggested tirzepatide had an edge, but indirect comparisons carry more uncertainty. SURMOUNT-5 gives prescribers and patients a direct data point to work from, and if you want to see how findings like these are being interpreted as they emerge, Mounjaro news today covers developments of this kind as they are published. NICE's committee discussion in TA1026 also references indirect comparisons favouring tirzepatide.

The caveat the trial itself carries: SURMOUNT-5 was open-label (participants knew which medicine they were on), and individual responses vary substantially. The question of which medicine suits a specific person is one a prescriber works through, not a headline figure. If you are weighing tirzepatide against other options, our treatment overview gives a balanced picture, and our prescribers are the right people to discuss your individual circumstances with.

Separately, the NHS England guidance on weight management injections has been updated in line with these developments and is a useful reference if you are navigating both the clinical evidence and the access landscape at the same time.